AlzeCure Pharma Reports Profit and Potential $3.2B Licensing Deals

6 sourcesUpdated Nov 12, 20261 min read

0

AlzeCure Pharma Reports Profit and Potential $3.2B Licensing Deals — © IJR

Sponsored

AlzeCure Pharma reported third-quarter 2026 sales of SEK 66.19 million and net income of SEK 52.27 million, compared with a loss in the year-earlier quarter; for the first nine months, sales were SEK 163.52 million and net income was SEK 110.76 million. The company’s interim report also highlighted two 2026 licensing and collaboration agreements: a deal with QuantumCell for its NeuroRestore program with potential value of $2.2 billion, excluding royalties, and an Eli Lilly agreement potentially worth more than $1 billion, also excluding royalties. AlzeCure said the QuantumCell agreement brought in $12 million, including a $5 million direct investment, and reported SEK 231.9 million in cash and equivalents at the end of September, up from SEK 59.2 million a year earlier.

Sponsored

In this story:

Sponsored

How it spread

Broke tradingview.com · Nov 11, 2:00 AM ET6 sources +25h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

More on this story

Back to News

Business

Rolls-Royce announces £1.5bn buyback, reaffirms 2026 guidance

Rolls-Royce announced an accelerated £1.5 billion share buyback, part of its existing £7 billion–£9 billion program, and reaffirmed its 2026 profit and free-cash-flow guidance. Strong engine demand has lifted its large-engine backlog to about 2,500, while flying hours and power-systems orders are also growing.

23 sources

Business

BAE Raises 2026 Cash-Flow Guidance 50% to £3B

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

BAE Systems raised its annual free cash flow forecast about 50% to £3 billion, citing customer advances and strong demand as governments increase defense spending. It kept its sales and profit growth outlook unchanged, while reporting £33 billion in orders so far this year and anticipating further agreements before year-end.

7 sources

Sponsored

Business

Anthropic IPO Valuation Could Reach $1.5 Trillion

Anthropic’s planned IPO is facing mounting uncertainty as investors reportedly push to lower its expected valuation from roughly $1.4 trillion–$1.5 trillion, with estimates ranging toward $1 trillion to $1.3 trillion amid a sell-off in AI stocks. Prediction-market odds for a near-term listing have also fallen, and reports say the company could reduce the offering or delay it.

437 sources